MAUNA KEA TECHNOLOGIES

Mauna Kea Technologies specializes in confocal laser endomicroscopy systems, which provide real-time, cellular-level imaging during endoscopic procedures. Their portfolio includes the Cellvizio 100 Series (with confocal miniprobes) and related accessories like the UroFlex™ N for urological applications, such as bladder and urethral examinations, as well as cystoscopy tools like the CystoFlex UHD R-C. These devices are designed to enhance diagnostic precision by enabling direct visualization of tissue at a microscopic level.

Mauna Kea Technologies is headquartered in France, which means its devices are subject to the European Union’s Medical Device Regulation (MDR) framework. The company’s products are classified as Class II or Class IIa, indicating moderate risk levels that require compliance with EU MDR requirements. This classification also influences registration in the EU’s EUDAMED database, ensuring transparency and traceability for regulatory authorities.

Mauna Kea Technologies’ devices are listed in the EU’s EUDAMED database, which is the official registry for medical devices under the EU MDR. Additionally, their products hold FDA 510(k) clearance in the United States, demonstrating compliance with U.S. regulatory standards. Listing in these registries ensures visibility for healthcare providers, regulators, and authorities, facilitating traceability, market surveillance, and post-market monitoring.

Under the EU Medical Device Regulation (MDR), Mauna Kea Technologies’ devices are classified as Class II or Class IIa. This classification reflects their moderate risk levels, requiring compliance with specific design controls, clinical evaluations, and post-market surveillance obligations. Class IIa devices, for example, may involve invasive procedures (like endomicroscopy) but are deemed lower risk than higher-class devices, necessitating rigorous documentation to ensure safety and performance.

An FDA 510(k) clearance indicates that Mauna Kea Technologies’ devices have been determined to be substantially equivalent to a legally marketed predicate device in the U.S., meeting FDA’s requirements for safety and effectiveness. In contrast, EUDAMED listing under the EU MDR serves as a public registry for all medical devices placed on the EU market, ensuring transparency about device details, manufacturers, and regulatory status. While 510(k) clearance is U.S.-specific, EUDAMED applies across the EU and reflects compliance with broader MDR requirements.